由中国消费经济高层论坛组委会支持、消费日报社主办的“骤变.突围”——“互联网+下的产品质量安全新常态”论坛暨2017年中国消费市场十大行业舆情热点发布、2018年“3.15中国消费市场影响力品牌(产品)”评选活动。活动将于2018年3月14日—15日在北京举行。本次活动将在全国选择家电、电商、手机、食品、服装、互联网金融、家居、旅游等十个重点行业,通过科技手段和大量数据,对舆情投诉集中问题和涉及主要品牌、事件进行公布。同时,活动还将通过网络投票方式,评选出“2018年度中国消费市场行业影响力品牌”等奖项,鼓励更多的企业在全新的时代背景下把握机遇、立足产品质量、强化品牌意识,成为消费者喜爱并信赖的品牌。

主办机构:消费日报社

媒体宣传:中央电视台、光明网、新华网、人民网、消费日报、央视网、搜狐网、新浪网、
中国县域经济报、中国经营报、中国信息报、北京晚报、腾讯视频、土豆视频、
爱奇艺等国家级媒体及地方主流媒体。
凯西医药咨询(上海)有限公司


 

Media Statement

1. Please provide a brief introduction to the history and corporate culture of Chiesi in Italy.
请简要介绍意大利凯西公司的发展历史和企业文化。
 
Chiesi Farmaceutici was established in Parma, Italy, in 1935 as a small laboratory with just two employees. Since then, Chiesi has transformed into an international pharmaceutical company with a presence in 26 countries across four continents. The company employs more than 5,000 people, of which nearly 700 are dedicated to research, development and regulatory activities, with a special focus on three primary therapeutic areas: respiratory, neonatology, and special care. In our 80-year history, three generations of the Chiesi family have continued to lead the company.
 
凯西医药公司(以下简称凯西或公司)于1935年在意大利帕尔马创办,最初是一个仅有两名员工的小型实验室。迄今为止,凯西已经发展成为一家国际化制药集团,业务遍布四大洲的26个国家,拥有超过5000名员工,其中有近700名员工专门从事研究、开发和监管合规业务。公司主要聚焦在三大主要治疗领域:呼吸道疾病、新生儿护理和特殊护理。 公司创办80多年来一直由Chiesi家族管理,现已传承到第三代。
 
Chiesi’s mission as a research-oriented pharmaceutical group, is to develop innovative pharmaceutical solutions to improve the quality of human life. We are firmly committed to operating in a socially and environmentally responsible manner to deliver high-quality services in healthcare and the life sciences. Our team is comprised of highly entrepreneurial and collaborative individuals committed to working with integrity and compassion.
 
凯西的首要目标是成为公认的研究型制药公司,能够研发并推广创新医药解决方案,从而改善人们的生活质量。我们坚持以对社会负责、对环境负责的原则开展经营,严格遵守最高的职业道德标准。我们的团队成员具有高度的创业精神和合作意识,用他们的诚信与热忱投入到工作中。
2. What attracted Chiesi to invest in China?
吸引凯西投资中国市场的因素有哪些?
 
China is a key strategic market for Chiesi and we are dedicated to developing innovative solutions that can have a significant impact on people’s lives. As the world’s second largest healthcare market, we continue to see growing consumer demand for innovative and effective medical solutions in therapy fields such as respiratory and neonatology in China.
 
 
 
 
 
中国是凯西公司的重要战略市场,而我们将继续扩大中国患者的治疗选择,并为多个尚未得到满足的医疗需求提供创新解决方案。中国目前是全球第二大医疗健康市场。我们认为在呼吸道疾病和新生儿护理等领域,消费者对创新且有效的医疗解决方案的需求将继续增长。
 
The development of a “Healthy China” is a key government priority and President Xi Jinping has consistently sought to prioritize people’s health and well-being in various official government policies. Our mission is in line with the “Healthy China 2030” plan to further enhance healthcare services in China.
 
“健康中国”倡议是中国政府的重点战略,在习近平主席的领导下,中国把人民的健康和福祉纳入到了多项政府政策中。“健康中国2030”规划反映了中央政府进一步提升中国医疗服务水平的决心,包括满足对创新医疗产品和方案的需求等。
 
For example, Chiesi played a leading role in introducing the first treatment for Neonatal Respiratory Distress Syndrome (NRDS) in China, a pathology that affects more than 7% of premature babies. This syndrome occurs most often in premature babies and can cause significant breathing difficulties with life threatening consequences if not adequately treated. This product has enabled us to treat over 500,000 babies diagnosed with NRDS in China. We have several new products in the pipeline, allowing us to offer patients more therapeutic options in China and providing innovative solutions for a variety of unmet medical needs.
 
例如,凯西在中国市场推出了首个新生儿呼吸窘迫综合症治疗方案,而在中国有超过7%的早产新生儿会罹患该病。呼吸窘迫综合症大多发生在早产新生儿身上,可以导致严重的呼吸困难,如果不能得到充分治疗,甚至会危及生命。凯西的这一产品已经成功地在中国治疗了50多万名患上呼吸窘迫综合症的婴儿,为提升公司在中国的声誉和业务奠定了良好的基础。
3. What is the strategic position of the Chinese market to Chiesi? Will there be more new drugs in China in the next five years?
中国市场对凯西的战略重要性有哪些?未来五年是否会向中国推出更多的新产品?
 
Chiesi has a presence in 26 countries globally, with China ranking high in terms of growth and investment. Currently, Chiesi in China contributes approximately 5% to the company’s global revenue, set to double by 2022 as we look to increase the development of Chiesi’s neonatology capabilities. Our respiratory products, including those developed to treat asthma and chronic obstructive pulmonary disease (COPD), have also seen strong growth in recent years.
 
凯西已在全球26个国家建立了子公司,中国目前排在第七位,贡献了集团全球收入(超过16亿欧元)的约5%。我们预计未来五年,中国市场的贡献将增长到10%,其中部分来自新生儿护理业务的迅速发展。我们的呼吸道产品,包括治疗哮喘以及慢性阻塞性肺病等产品在近年来也实现了强劲的增长。
 
 
 
 
To meet unmet needs in China and using our global expertise, we plan to launch new products in the therapeutic fields of neonatalogy and respiratory. We are also looking to explore new ventures in the fields of special care and rare disease, marking an exciting new chapter for Chiesi in China.
 
我们计划在未来几年陆续推出新的新生儿和呼吸道产品。我们也将开始探索特殊护理和罕见病方面的产品,为凯西开启在中国发展的新篇章。
4. What suggestions would you give to foreign companies wishing to enter the market in China?
对于希望进入中国市场的外国公司,您有哪些建议?
 
China can be a complex landscape to navigate for pharmaceutical companies entering the market. The commercialization of a number of pharmaceutical products requires a significantly longer processing and approval period, compared to other markets. However, in recent years, the government has made great strides in addressing various market challenges and streamlining regulatory processes.
 
对于从未试水中国医疗市场的医药公司来说,中国市场状况非常复杂。例如,很多医药产品在商业化过程中,需要的审批时间比很多其他市场长得多。但近年来,中国政府也在大刀阔斧地改革,努力解决这些市场挑战,并简化监管和审批流程。
 
Factors such as stable macroeconomic growth, rising income levels, an expanding middle class, and growing consumer demand for innovative medical treatments all make China a highly attractive market to pharmaceutical companies. This is also why some of the largest pharmaceutical companies in the world have already established their presence in the country.
 
中国对全球的制药公司都具有极大的吸引力,原因有很多:中国宏观经济增长稳定、收入水平不断提高、中产阶级日益壮大以及消费者对创新医疗方案的需求也在不断增长。这也是一些全球最大的制药企业在中国建立业务的原因。
 
Like in other markets, companies must take a local approach to navigating the China market. Partnering with a domestic partner can help companies navigate and build their understanding of the local market and  help to bring new medical solutions and products to China effectively.
 
就像在进入其他市场一样,制药公司需要采用“当地化”的方式来赢得中国市场。与拥有广泛经验,熟悉当地市场的国内伙伴合作可以帮助企业建立对当地市场的了解,更加顺畅地向中国人民介绍新的医疗方案和产品。